Port Moresby

Researchers are evaluating the safety and effectiveness of high dose primaquine treatment in patients with Vivax Malaria who have different levels of G6PD enzyme activity. This Phase 4 observational study focuses on patients with intermediate G6PD activity (30-70%) and those with G6PD deficiency (less than 30%). The study aims to understand how well primaquine works and how safe it is for these groups. Patients with intermediate G6PD activity will receive schizontocidal treatment plus a high dose of primaquine at 1 mg/kg daily for 7 days. Those with G6PD deficiency will be treated with schizontocidal treatment plus weekly primaquine at a dose of 0.75 mg/kg for 8 weeks. Treatments are given according to the patient's enzyme activity level. Participants will be followed for six months to monitor safety and treatment effectiveness. Researchers will assess outcomes including safety measures and the ability of the treatment to control malaria. The study includes regular health checks, monitoring of hemoglobin levels, and tracking any side effects or complications over the study period.